3 completed, 1 terminated. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Lanraplenib: new trials by email Literature Review of Lanraplenib trials Research Report on Lanraplenib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) Lanraplenib, Gilteritinib - Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Kronos Bio | 24 | 2022-08-05 | 2024-08-07 |
| Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN) Filgotinib, Lanraplenib, Filgotinib placebo - Lupus Membranous Nephropathy | Phase 2 | Completed | Gilead Sciences | 9 | 2017-10-06 | 2020-05-18 |
| Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE) Lanraplenib, Filgotinib, Lanraplenib placebo - Cutaneous Lupus Erythematosus | Phase 2 | Completed | Gilead Sciences | 47 | 2017-05-24 | 2020-06-09 |
| Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome Lanraplenib, Filgotinib, Tirabrutinib - Sjogren's Syndrome | Phase 2 | Completed | Gilead Sciences | 152 | 2017-05-01 | 2020-10-23 |
Leukemia, Myeloid, Acute (1) · Lupus Erythematosus, Cutaneous (1) · Sjogren's Syndrome (1)
Gilead Sciences (3) · Kronos Bio (1)
United States (4) · Spain (2) · Canada (1) · Poland (1) · United Kingdom (1)
PMID 33380521, PMID 34498056, PMID 35377447
2016 (1)